Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

Fig. 1

Timeline of the PANGAEA main study and pharmacoeconomic sub-study. Main study and sub-study will include 4,000 and 800 RRMS patients treated with fingolimod (0.5 mg/daily), and the observational phase will be 60 months and 24 months, respectively (* in the pharmacoeconomic sub-study, recruitment will end after 800 patients)

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us